Erasca receives US patent for pan-RAS molecular glue ERAS-0015

Erasca Inc. (NASDAQ: ERAS) announced that the U.S. Patent and Trademark Office issued Patent No. 12,458,647 covering its pan-RAS molecular glue ERAS-0015. The patent protects the composition of matter for ERAS-0015 and related compositions until September 2043.

The San Diego-based clinical-stage precision oncology company in-licensed ERAS-0015 in May 2024. The drug candidate is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors.

According to the company, preclinical studies showed ERAS-0015 demonstrated approximately 8-21 times higher binding affinity to cyclophilin A compared to other pan-RAS molecular glues in development. The compound also showed approximately 5 times greater potency in RAS inhibition and achieved comparable tumor growth inhibition at doses one-tenth to one-fifth of competing treatments.

"This U.S. patent is a foundational milestone for our ERAS-0015 program," said Jonathan E. Lim, Erasca's chairman, CEO, and co-founder. "Covering ERAS-0015 until at least 2043, this patent is among a series of patent filings designed to form a strong and durable intellectual property portfolio for our RAS-targeting franchise."

The company expects initial Phase 1 monotherapy data for ERAS-0015 and its pan-KRAS inhibitor ERAS-4001 in 2026. ERAS-4001 is being evaluated in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors.

Erasca focuses on discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers. The patent may be subject to adjustments or extensions that could extend protection beyond 2043.

You May Also Be Interested In

• Erasca Inc (ERAS) PT Raised to $21 at Guggenheim
• JPMorgan Upgrades FOX Corp. (FOXA) to Overweight
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold